Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2014 1
2016 1
2017 3
2018 2
2019 6
2020 1
2021 2
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.
Parisi A, Palluzzi E, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P, Porzio G, Ficorella C, Cannita K. Parisi A, et al. Among authors: palluzzi e. Clin Transl Oncol. 2020 Jan;22(1):158-162. doi: 10.1007/s12094-019-02122-x. Epub 2019 Apr 30. Clin Transl Oncol. 2020. PMID: 31041717 Clinical Trial.
New medical approaches in advanced ovarian cancer.
Corrado G, Palluzzi E, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. Corrado G, et al. Among authors: palluzzi e. Minerva Med. 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Minerva Med. 2019. PMID: 31124637 Review.
Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Corrado G, et al. Among authors: palluzzi e. Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158. doi: 10.1080/14737140.2017.1398088. Epub 2017 Nov 6. Expert Rev Anticancer Ther. 2017. PMID: 29086618 Review.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: palluzzi e. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
16 results